NCT01499537

Brief Summary

At this time, endoscopic retrograde cholangiopancreatography (ERCP) stay the gold standard method to achieve biliary drainage in case of malignant or benign stricture. When ERCP fail or if the major papilla is not suitable, percutaneous transhepatic biliary drainage (PTBD) is the most commonly used alternative, surgery having higher morbidity and mortality rates, unacceptable especially in palliative situation. Recent developments in interventional endoscopic ultrasonography (EUS) allow new endoluminal approaches to pancreatic-biliary structures, such as cysto-enterostomy or pancreatic-enterostomy. More recently were described the possibility to realize EUS-guided biliary drainage, through the duodenal or the gastric wall. Advantages of the EUS-guided approach are to be realizable even the papilla is not suitable endoscopically (duodenal stricture or post-surgical status) and to allow if necessary extra-tumoral non anatomic drainage (hepaticogastrostomy). This technique is actually an alternative to PTBD. In comparison of the PTBD, EUS-guided route seems to have less morbidity and to avoid external biliary drainage. Indeed, the morbidity rate of the percutaneous biliary drainage and the EUS-guided biliary drainage range respectively from 25 to 35% and from 0 to 23%. However, none study compare prospectively both techniques. Aims of this study are to compare the morbidity rate, feasibility and efficacy of these techniques.

Trial Health

90
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
65

participants targeted

Target at P50-P75 for not_applicable

Timeline
Completed

Started Jan 2011

Longer than P75 for not_applicable

Geographic Reach
2 countries

3 active sites

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

January 1, 2011

Completed
9 months until next milestone

First Submitted

Initial submission to the registry

September 16, 2011

Completed
3 months until next milestone

First Posted

Study publicly available on registry

December 26, 2011

Completed
4.1 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

February 1, 2016

Completed
29 days until next milestone

Study Completion

Last participant's last visit for all outcomes

March 1, 2016

Completed
Last Updated

May 19, 2016

Status Verified

February 1, 2016

Enrollment Period

5.1 years

First QC Date

September 16, 2011

Last Update Submit

May 18, 2016

Conditions

Keywords

Stenosis of biliary ways

Outcome Measures

Primary Outcomes (1)

  • Morbidity rate

    Morbidity rate during 30 post-operative days

    30 days

Secondary Outcomes (4)

  • efficacy

    15 days

  • feasibility

    up to 3 days

  • biliary drainage duration

    up to 1 month

  • quality of life

    30 days

Study Arms (2)

Percutaneous Drainage

ACTIVE COMPARATOR

Percutaneous Transhepatic Biliary Drainage (PTBD)

Device: biliary drainage

EUS-guided drainage

EXPERIMENTAL

endoscopic ultrasonography guided biliary drainage through the duodenal or the gastric wall

Device: EUS guided biliary drainage

Interventions

percutaneous transhepatic biliary drainage (PTBD)

Percutaneous Drainage

endoscopic ultrasonography guided biliary drainage through the duodenal or the gastric wall

EUS-guided drainage

Eligibility Criteria

Age18 Years+
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • age \>= 18
  • Karnofsky \>= 50%
  • biliary stenosis (malignant or benign stricture)with failure of endoscopic retrograde cholangiopancreatography
  • signed informed consent

You may not qualify if:

  • isolated biliary stenosis of right hepatic canal
  • percutaneous biliary drainage \< 10 days
  • laparotomy \< 10 days
  • contra-indication to the procedure
  • pregnant women

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (3)

Institut Paoli-Calmettes

Marseille, 13009, France

Location

Hopital Nord

Marseille, 13020, France

Location

Centre Hospitalier Princesse Grace

Monaco, 98000, Monaco

Location

Related Links

MeSH Terms

Conditions

Jaundice

Condition Hierarchy (Ancestors)

HyperbilirubinemiaPathologic ProcessesPathological Conditions, Signs and SymptomsSkin ManifestationsSigns and Symptoms

Study Officials

  • Erwan BORIES, MD

    Institut Paoli-Calmettes

    PRINCIPAL INVESTIGATOR

Study Design

Study Type
interventional
Phase
not applicable
Allocation
RANDOMIZED
Masking
NONE
Purpose
TREATMENT
Intervention Model
PARALLEL
Sponsor Type
OTHER
Responsible Party
SPONSOR

Study Record Dates

First Submitted

September 16, 2011

First Posted

December 26, 2011

Study Start

January 1, 2011

Primary Completion

February 1, 2016

Study Completion

March 1, 2016

Last Updated

May 19, 2016

Record last verified: 2016-02

Locations